ARVINAS, INC. (ARVN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 8 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 3, 2026before open 34 8-K
Q2 FY2026Tue, Aug 4, 2026before open 35 8-K
Q1 FY2026Tue, May 12, 2026before open 42 8-K
Q4 FY2025Tue, Feb 24, 2026before open 55 8-K
Q3 FY2025Wed, Nov 5, 2025before open 36 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Thu, May 1, 2025before open 31 8-K
Q4 FY2024Tue, Feb 11, 2025before open 42 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026 and 2027 – – Demonstrated novel oculomotor and biomarker movement with ARV-102 Phase 1 clinical data in patients with Parkinson’s disease with oral presentation at MDS conference – – Company to host conference call today " exhibit
Q3 FY2026 "Anticipate initiation of dosing patients in the combination cohort with pembrolizumab (mid-2027)." exhibit
Q3 FY2026 "Financial Guidance Based on its current operating plan, Arvinas believes its cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, is sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028." exhibit
Q2 FY2026 "Document Exhibit 99.1 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to ho" exhibit
Q2 FY2026 "Financial Guidance Based on its current operating plan, Arvinas believes its cash, cash equivalents, and marketable securities as of June 30, 2026, is sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ARVN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ARVN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ARVN earnings date badge

HTML

<a href="https://veritasdata.dev/company/ARVN/"><img src="https://veritasdata.dev/embed/ARVN.svg" alt="ARVN earnings date" width="240" height="56"></a>

Markdown

[![ARVN earnings date](https://veritasdata.dev/embed/ARVN.svg)](https://veritasdata.dev/company/ARVN/)

Script

<script async src="https://veritasdata.dev/embed/ARVN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ARVN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.